Metallothionein-IIA promotes neurite growth via the megalin receptor

Exp Brain Res. 2007 Nov;183(2):171-80. doi: 10.1007/s00221-007-1032-y. Epub 2007 Jul 19.

Abstract

Metallothionein (MT)-I/II has been shown to be neuroprotective and neuroregenerative in a model of rat cortical brain injury. Here we examine expression patterns of MT-I/II and its putative receptor megalin in rat retina. At neonatal stages, MT-I/II was present in retinal ganglion cells (RGCs) but not glial or amacrine cells; megalin was present throughout the retina. Whilst MT-I/II was absent from adult RGC in normal animals and after optic nerve transection, the constitutive megalin expression in RGCs was lost following optic nerve transection. In vitro MT-IIA treatment stimulated neuritic growth: more RGCs grew neurites longer than 25 microm (P < 0.05) in dissociated retinal cultures and neurite extension increased in retinal explants (P < 0.05). MT-IIA treatment of mixed retinal cultures increased megalin expression in RGCs, and pre-treating cells with anti-megalin antibodies prevented MT-IIA-stimulated neurite extension. Our results indicate that MT-IIA stimulates neurite outgrowth in RGCs and may do so via the megalin receptor; we propose that neurite extension is triggered via signal transduction pathways activated by the NPxY motifs of megalin's cytoplasmic tail.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Antibodies / pharmacology
  • Cells, Cultured
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Female
  • In Vitro Techniques
  • Low Density Lipoprotein Receptor-Related Protein-2 / immunology
  • Low Density Lipoprotein Receptor-Related Protein-2 / physiology*
  • Male
  • Metallothionein / pharmacology*
  • Neurites / drug effects*
  • Optic Nerve Injuries / metabolism
  • Optic Nerve Injuries / pathology
  • Optic Nerve Injuries / physiopathology
  • Rats
  • Retinal Ganglion Cells / cytology*
  • Signal Transduction / drug effects
  • Up-Regulation / drug effects
  • Up-Regulation / physiology

Substances

  • Antibodies
  • Low Density Lipoprotein Receptor-Related Protein-2
  • Metallothionein